Patten & Patten INC Raised Holding in Abbott Laboratories (ABT) by $9.22 Million as Share Price Rose

Abbott Laboratories (NYSE:ABT) LogoInvestors sentiment decreased to 0.91 in 2018 Q4. Its down 0.05, from 0.96 in 2018Q3. It dropped, as 61 investors sold ABT shares while 576 reduced holdings. 143 funds opened positions while 434 raised stakes. 1.29 billion shares or 4.79% more from 1.23 billion shares in 2018Q3 were reported. Mackenzie Financial Corp accumulated 21,163 shares or 0% of the stock. Suncoast Equity, Florida-based fund reported 4,345 shares. First Utd National Bank Tru invested in 1.02% or 20,068 shares. Puzo Michael J accumulated 98,504 shares. Parallax Volatility Advisers Limited Partnership reported 0.02% of its portfolio in Abbott Laboratories (NYSE:ABT). 9,681 are held by Loudon Inv Management Limited. 266 were accumulated by Wolverine Asset Management Lc. Moreover, Papp L Roy & Associate has 0.15% invested in Abbott Laboratories (NYSE:ABT) for 9,825 shares. Strategy Asset Managers Lc has invested 0.77% in Abbott Laboratories (NYSE:ABT). Shayne And Ltd Liability Corporation holds 0.15% of its portfolio in Abbott Laboratories (NYSE:ABT) for 2,800 shares. 1.88 million were accumulated by State Of Tennessee Treasury Department. Hilltop Holdg invested 0.11% in Abbott Laboratories (NYSE:ABT). 240,718 were reported by Eastern Bank & Trust. Comerica Securities owns 50,001 shares for 0.48% of their portfolio. Barrett Asset Ltd Liability Com invested in 108,393 shares.

Since November 28, 2018, it had 1 buying transaction, and 2 selling transactions for $22.47 million activity. The insider WHITE MILES D sold 142,341 shares worth $10.30M. The insider Stratton John G bought 3,455 shares worth $249,875.

Patten & Patten Inc increased its stake in Abbott Laboratories (ABT) by 145.41% based on its latest 2018Q4 regulatory filing with the SEC. Patten & Patten Inc bought 128,055 shares as the company’s stock rose 7.95% with the market. The institutional investor held 216,119 shares of the major pharmaceuticals company at the end of 2018Q4, valued at $15.63M, up from 88,064 at the end of the previous reported quarter. Patten & Patten Inc who had been investing in Abbott Laboratories for a number of months, seems to be bullish on the $135.24B market cap company. The stock decreased 0.33% or $0.25 during the last trading session, reaching $76.66. About 1.87 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 33.73% since May 8, 2018 and is uptrending. It has outperformed by 29.36% the S&P500.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: which released: “8 Stocks To Watch For April 17, 2019 – Benzinga” on April 17, 2019, also with their article: “Abbott (ABT) Tops Q1 EPS by 2c, Offers Outlook –” published on April 17, 2019, published: “AbbVie: This 5% Yielding Dividend Aristocrat Is Undervalued – Seeking Alpha” on April 09, 2019. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: and their article: “Analyst Note Fosters Doubts About Dow Inc Stock –” published on April 10, 2019 as well as‘s news article titled: “Can You Simply Add To Your High Quality Dividend Growth Stocks When They’re Down, Because They’re Down? – Seeking Alpha” with publication date: April 20, 2019.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 8 analysts covering Abbott Labs (NYSE:ABT), 7 have Buy rating, 1 Sell and 0 Hold. Therefore 88% are positive. Abbott Labs had 15 analyst reports since November 27, 2018 according to SRatingsIntel. The firm has “Sell” rating by Citigroup given on Wednesday, January 2. Goldman Sachs upgraded the shares of ABT in report on Friday, November 30 to “Buy” rating. The company was maintained on Tuesday, December 4 by Morgan Stanley. The firm earned “Overweight” rating on Wednesday, January 2 by Morgan Stanley. Cowen & Co maintained the shares of ABT in report on Thursday, March 14 with “Buy” rating. The stock has “Buy” rating by Barclays Capital on Friday, March 8.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.